PATENT CLAIM ANALYSIS

Application Number: 15860781
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["544", "331000"]

Abstract:
Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X 1 , X 2 , X 3  and X 4  have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Claim (Index 23):
The method of  claim 21 , wherein the RET fusion protein is selected from the group consisting of BCR-RET, CLIP1-RET, KIF5B-RET, CCDC6-RET, NCOA4-RET, TRIM33-RET, ERC1-RET, FGFR1OP-RET, RET-MBD1, RET-RAB61P2, RET-PRKAR1A, RET-TRIM24, RET-GOLGA5, HOOK3-RET, KTN1-RET, TRIM27-RET, AKAP13-RET, FKBP15-RET, SPECC1L-RET, TBL1XR1/RET, CEP55-RET, CUX1-RET, KIAA1468-RET, RFG8/RET, ACBD5-RET, PTC1ex9-RET, MYH13-RET, PIBF1-RET, KIAA1217-RET, and MPRIP-RET.

Metadata:
- Claim Count in Document: 77.0
- Percentile: 86.0
- Lexical Diversity: 1.63462
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15860849', '15858658', '15860852', '15860808', '15860894']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.864482239431348
- 35 USC 102 Novelty (BERT): 0.6367207377219544
- Combined Prediction Score: 0.8417060892604087
- Mean Citation Score: 555.9032100000002
- Max Citation Score: 590.9769
- Similarity Product: 582.3203640660882

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test